Malarex (Proguanil Hydrochloride, Atovaquone)

• Malarex combines proguanil and atovaquone to address malaria, a parasitic disease transmitted by mosquitoes.
• Prevention of malaria infection: provides prophylactic protection for travelers and residents in endemic areas when taken before, during, and after exposure.
• Treatment of acute uncomplicated malaria caused by Plasmodium falciparum: used as a curative regimen to clear parasitemia and resolve symptoms.
• Travel‑related malaria risk reduction: reduces the likelihood of contracting malaria during short‑term trips to high‑risk regions.

• Atovaquone interferes with the mitochondrial electron transport chain of Plasmodium parasites, collapsing the parasite’s energy production. Proguanil is converted in the body to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme, blocking folate synthesis and DNA replication. The simultaneous disruption of energy metabolism and folate pathways produces a synergistic antimalarial effect, enhancing parasite clearance and reducing the chance of resistance development.

Malarex may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset that may resolve without treatment.
• Headache: transient cranial discomfort often relieved with simple analgesics.
• Abdominal pain: intermittent cramps or discomfort in the abdomen.
• Diarrhea: loose, watery stools that are usually self‑limiting.

Serious or Rare Side Effects

• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, requiring immediate medical attention.
• Hematologic abnormalities: including neutropenia or thrombocytopenia, which may predispose to infection or bleeding.
• Liver enzyme elevation: significant increase in transaminases indicating possible hepatic injury.

When prescribing Malarex, several precautionary measures should be observed to ensure safe use.

• Assess renal and hepatic function: evaluate liver and kidney status before initiating therapy.
• Review patient’s medication history: identify drugs that may interact or increase toxicity.
• Monitor for hypersensitivity: watch for rash, itching, or swelling during treatment.
• Use with caution in children: dosage adjustments may be required based on weight and age.
• Avoid in known hypersensitivity to proguanil or atovaquone: discontinue if allergic reaction occurs.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Malarex can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Rifampicin: induces hepatic enzymes, markedly reducing atovaquone and proguanil plasma levels.
• Antiretroviral protease inhibitors (e.g., ritonavir): may increase proguanil concentrations, raising toxicity risk.
• High‑dose vitamin A supplements: can enhance atovaquone toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: may potentiate anticoagulant effect; monitor INR closely.
• Sulfonamides: concurrent use may increase risk of hematologic side effects.
• St. John’s wort: may lower drug exposure; adjust therapy if clinically indicated.